ASX Announcement 28 October 2026 Quarterly Activities Report for the period ending 30 September 2026 Neurotech International Limited (ASX: NTI) (“Neurotech” or “the Company”), a clinical-stage biopharmaceutical company focused on paediatric neurological disorders, is pleased to present its...
Quarterly Activities/Appendix 4C Cash Flow Report
Filed with ASX ·
6ix is reading this filing.
Neurotech International Ltd. on 6ix
Earlier from Neurotech International
- NTI Doses First Patient in Phase 3 Beyond Harmony ASD Study
- Receipt of Binding Commitments for $4.5m Placement
- Neurotech secures $3.15 million R&D tax incentive loan
- US FDA clears IND for NTI164
- NTI secures Notices of Allowance for US patent applications
Follow Neurotech International into a list and get an email when it puts out news.
Follow Neurotech International